XML 36 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1
Compensatory Equity Incentive Plan and Other Equity Incentives (Tables)
9 Months Ended
Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of share based compensation award plans

These plans are summarized below:

 

         Award Shares   Available for 
        Outstanding   Issuance 
     Award    at March 31,   at March 31, 
  Equity Compensation Arrangement  Authorized   2017   2017 
  Amended and Restated Omnibus Incentive Plan   3,915,625    2,602,968    633,701 
  Employee Stock Purchase Plan   400,000        377,988 
                  
      4,315,625    2,602,968    1,011,689 

Schedule of stock options fair value assumptions

For stock options granted in the nine month periods ended March 31, 2017 and 2016, we estimated the fair value of each stock option as of the date of grant using the following assumptions:

 

   Nine months   Nine months 
   March 31, 2017   March 31, 2016 
Weighted average expected volatility   77% - 83%    68% - 103% 
Dividend yields   0%    0%
Weighted average risk-free interest rate   1.18% - 1.90%    0.37% - 1.49% 
Weighted average expected term, in years   7.49    4.29 - 7.50 

Schedule of share based compensation awards activity

A summary of the activity for share-based compensation awards in the nine months ended March 31, 2017 is presented below:

               Restricted 
   Stock Options   Stock Units (RSUs)  
         Weighted    Weighted         Weighted 
         Average    Average         Average 
         Exercise    Remaining         Remaining 
         Price    Contract         Contract 
     Shares     (per share)    Life (YRS)     Shares     Life (YRS) 
June 30, 2016   819,260   $1.90    5.6    1,311,795    0.9 
                          
Granted   339,926   $1.61    9.6    230,772    2.6 
Exercised               (33,785)    
Cancelled/Forfeited   (65,000)  $4.26             
March 31, 2017   1,094,186   $1.67    6.6    1,508,782    1.0 
                          
Awards exercisable/vested as of                         
March 31, 2017   850,425   $1.70    5.9    1,069,870     
                          
Awards unexercisable/unvested as of                         
March 31, 2017   243,761   $1.56    8.8    438,912    1.0 
    1,094,186              1,508,782      

 

    Stock Options   RSUs   All Awards 
Weighted average fair value of share awards granted in period   $1.15   $1.56   $1.32 

Schedule of share based compensation future cost to be recognized

We expect to recognize the compensation cost as follows:

 

    Stock        
    Options   RSUs   Total 
              
Three months ended June 30, 2017    12,597    63,735    76,332 
                 
Year ended June 30, 2018    39,612    244,917    284,529 
                 
Year ended June 30, 2019    17,784    144,984    162,768 
                 
Year ended June 30, 2020    3,243    29,989    33,232 
                 
Year ended June 30, 2021    242        242 
    $73,478   $483,625   $557,103 

Summary of the number and weighted average grant date fair values regarding our unexercisable/unvested awards

The following table is a summary of the number and weighted average grant date fair values regarding our unexercisable/unvested awards as of March 31, 2017 and changes during the nine months then ended:

 

Unexercisable/unvested awards  Stock
Options
Shares
   RSU Shares   Total
Shares
   Weighted-Average
Grant Date Fair Values
(per share)
 
June 30, 2016   182,250    441,599    623,849   $1.35 
Granted   339,926    230,772    570,698   $1.32 
Vested   (274,665)   (233,459)   (508,124)  $1.28 
Cancelled/Forfeited   (3,750)       (3,750)  $1.08 
March 31, 2017   243,761    438,912    682,673   $1.38 

Schedule of share based compensationincluded in the consolidated statements of comprehensive income

The following table shows total stock-based compensation expense for the nine months ended March 31, 2017 and 2016 included in the consolidated statements of comprehensive income:

 

   Nine months ended   Nine months ended 
   March 31,   March 31, 
   2017   2016 
         
 Stock options  $34,882   $37,125 
 RSUs   284,300    224,490 
      Total  $319,182   $261,615 
           
 The amounts above were included in:          
 Selling, general & administrative  $315,429   $260,450 
 Cost of sales   2,792    238 
 New product development   961    927 
   $319,182   $261,615